Nama's AI scorecard currently rates Novartis Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NVS's P/E ratio?

Novartis trades at a trailing price-to-earnings ratio of 19.0.

When does NVS report earnings?

Novartis's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $2.23.

What is the NVS price target?

The median analyst price target from 10 analysts is $153.00, with a range of $130.00 – $185.00.

Is NVS Shariah compliant?

Nama's AAOIFI-style screen reads Novartis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does NVS pay a dividend?

Yes — Novartis's dividend yield is 2.9%.

Nama Insights

Novartis (NVS)

Healthcare · Drug Manufacturers General · NYSE

Novartis (NVS) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $307.00B, a trailing price-to-earnings ratio of 19.0 and a free-cash-flow yield of 4.8%. Over the most recent reported fiscal year, revenue grew 9.6% and free cash flow per share grew 14.9%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.8/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +13.2% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-4.6%

How far the last close sits under the highest price of the past five years.

Market cap	$307.00B
Trailing P/E	19.0
Price / book	8.2
Price / sales	5.3
FCF yield	4.8%
Dividend yield	2.9%
Gross margin	74.9%
Operating margin	25.2%
Net margin	17.5%
Revenue growth (YoY)	+9.6%
Revenue growth (3-yr annual)	+9.2%
EPS growth (YoY)	+15.0%
FCF/share growth (YoY)	+14.9%
Beta	0.5
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers General

NVS earnings

Next report: Feb 3, 2027 (Q4 2026, EPS estimate $2.23). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$2.46	$2.24	+9.8%	$15.03B
Q2 2026	Jul 20, 2026	$2.41	$2.15	+12.1%	$14.95B
Q1 2026	Apr 27, 2026	$1.65	$1.65	+0.0%	$13.52B
Q4 2025	Feb 4, 2026	$2.03	$2.00	+1.5%	$13.86B

NVS analyst price target

Median target $153.00 from 10 analysts, ranging $130.00 – $185.00.

Drug Manufacturers General peers

Ticker	Company	Market cap	P/E
LLY	Eli Lilly	$1.21T	42.4
JNJ	Johnson & Johnson	$664.95B	25.9
ABBV	AbbVie	$514.92B	22.7
MRK	Merck	$361.73B	47.0
AZN	AstraZeneca	$289.14B	38.8
AMGN	Amgen	$249.05B	19.9
GILD	Gilead Sciences	$207.00B	—
NVO	Novo Nordisk A/S	$177.74B	11.0

Explore live NVS data on Nama Insights →

Recent Congressional trades

Novartis trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Alan Armstrong	Senate	Buy	$15,001 - $50,000	Jul 21, 2026
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Oct 22, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Oct 22, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Daniel Goldman	House	Sell	$50,001 - $100,000	Aug 13, 2023

NVS FAQ

Is NVS a buy?: Nama's AI scorecard currently rates Novartis Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NVS's P/E ratio?: Novartis trades at a trailing price-to-earnings ratio of 19.0.
When does NVS report earnings?: Novartis's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $2.23.
What is the NVS price target?: The median analyst price target from 10 analysts is $153.00, with a range of $130.00 – $185.00.
Is NVS Shariah compliant?: Nama's AAOIFI-style screen reads Novartis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does NVS pay a dividend?: Yes — Novartis's dividend yield is 2.9%.